Acyclic Nitrogen Or Chalcogen Bonded Directly To The -c(=x)- Group Patents (Class 548/369.7)
-
Patent number: 12133852Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.Type: GrantFiled: November 4, 2020Date of Patent: November 5, 2024Assignee: EpiVario, Inc.Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
-
Patent number: 11578051Abstract: The present invention provides a thiophene carboxamide compound of the following General Formula (I), which is a novel fluorine-substituted biphenyl carboxamide-based compound, and provides a useful compound, as an agricultural and horticultural plant disease control agent, exhibiting an excellent control effect at a low dose. wherein, R, R1, R2, R3, Xm, and Y are each as defined in the specification.Type: GrantFiled: October 7, 2019Date of Patent: February 14, 2023Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, FARMHANNONG CO., LTDInventors: Jae Wook Ryu, Hyun Suk Yeom, Myeong Su Shin, In Young Oh, Ki-Ju Park, Min-Young Song, Do-Hyoung Kim, Han-Young Lee, Kyung-Jin Jun
-
Patent number: 10087146Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.Type: GrantFiled: April 19, 2017Date of Patent: October 2, 2018Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
-
Publication number: 20150105252Abstract: Disclosed is a method for controlling the growth of undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of a compound of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein A, R1, Q and J are as defined in the disclosure. Also disclosed is a method wherein the compound of Formula 1 (i.e. in a herbicidally effective amount) is comprised in a herbicidal composition further comprising at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents. Also disclosed are compound of Formula 1 (including all stereoisomers), including N-oxides and salts thereof, their use as herbicides wherein A, R1, Q and J are as defined in the disclosure.Type: ApplicationFiled: October 15, 2014Publication date: April 16, 2015Inventor: THOMAS MARTIN STEVENSON
-
Publication number: 20150099766Abstract: The invention relates to compounds of the general formula (I), in which the radicals A1, A2, A3, A4, Lm, Q, R1, T and U have the meaning given in the description and to the use of the compounds for controlling animal pests. In addition, the invention relates to processes and intermediates for the preparation of the compounds according to formula (I).Type: ApplicationFiled: December 15, 2014Publication date: April 9, 2015Inventors: Michael MAUE, Isabelle ADELT, Wolfgang GIENCKE, Markus HEIL, Peter JESCHKE, Bernd-Wieland KRÜGER, Friedrich August MÜHLTHAU, Alexander SUDAU, Klaus RAMING, Ulrich EBBINGHAUS-KINTSCHER, Martin ADAMCZEWSKI, Arnd VOERSTE, Ulrich GÖRGENS, Tobias KAPFERER, Mark Wilhelm DREWES, Angela BECKER, Eva-Maria FRANKEN
-
Publication number: 20150018561Abstract: The present invention pertains to novel enaminoketones containing a CF3O-group, novel pyrazole-derivatives containing a CF3O group as well as to a novel process for their preparation comprising aminoformylation of CF3O-ketones and cyclization of the obtained CF3O-enaminoketones with hydrazines to trifluoromethoxy pyrazoles.Type: ApplicationFiled: February 13, 2013Publication date: January 15, 2015Applicants: BAYER INTELLECTUAL PROPERTY GMBH, CENTRE NATIONAL DE LA RECHERCHE SCENTIFIQUEInventors: Sergii Pazenok, Bernard Langlois, Thierry Billard, Julien Barbion, Olivier Marrec, Jean-Pierre Vors
-
Publication number: 20140364603Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
-
Patent number: 8841332Abstract: The present invention relates to fungicide N-(2-phenoxyethyl)carboxamide derivatives of formula (I), their aza, thia and sila analogs, their process of preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. Formula (1) wherein A, T, W, X, n and Z3 to Z7 represent various substituents.Type: GrantFiled: July 30, 2009Date of Patent: September 23, 2014Assignee: Bayer Intellectual Property GmbHInventors: Samir Bennabi, Jurgen Benting, Stephane Brunet, Philippe Desbordes, Peter Dahmen, Stephanie Gary, Marie-Claire Grosjean-Cournoyer, Rachel Rama, Philippe Rinolfi, Valerie Toquin, Arnd Voerste, Ulrike Wachendorff-Neumann
-
Patent number: 8796468Abstract: Disclosed is an adamantanamine derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. Disclosed is a compound represented by the formula (II): wherein R10 is a group represented by the formula: —(CR13R14)m-NR12—R11 or the like.Type: GrantFiled: December 20, 2010Date of Patent: August 5, 2014Assignee: Shionogi & Co., Ltd.Inventors: Tomoyuki Ogawa, Koji Masuda
-
Publication number: 20140206738Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.Type: ApplicationFiled: January 23, 2014Publication date: July 24, 2014Applicants: Karl-Franzens-Universität Graz, Technische Universität GrazInventors: Martina SCHWEIGER, Matthias ROMAUCH, Robert ZIMMERMANN, Nicole MAYER, Rolf BREINBAUER
-
Publication number: 20140128616Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: SANOFIInventors: Sven RUF, Josef PERNERSTORFER, Thorsten SADOWSKI, Georg HORSTICK, Herman SCHREUDER, Christian BUNING, Thomas OLPP, Bodo SCHEIPER, Klaus WIRTH
-
Patent number: 8686018Abstract: The present invention provides compounds of Formula I: along with pharmaceutical compositions containing the same, and methods of use thereof in subjects in need of treatment.Type: GrantFiled: March 12, 2013Date of Patent: April 1, 2014Assignee: Eisai R&D Management Co., Ltd.Inventors: Mark Spyvee, Takashi Satoh, Jonathan Eric Carlson
-
Publication number: 20140088153Abstract: The invention relates to compounds of the general formula (I) in which the radicals A1, A2, A3, A4, L, Q, R1, T and W have the meaning given in the description and to the use of the compounds for controlling animal pests. The invention furthermore relates to processes and intermediates for preparing the compounds of formula (I).Type: ApplicationFiled: March 12, 2012Publication date: March 27, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Michael Maue, Isabelle Adelt, Markus Heil, Peter Jeschke, Tobias Kapferer, Friedrich August Muehlthau, Alexander Sudau, Olga Malsam, Peter Loesel, Arnd Voerste, Ulrich Goergens
-
Patent number: 8664257Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: GrantFiled: January 26, 2011Date of Patent: March 4, 2014Assignee: SanofiInventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Thomas Olpp, Bodo Scheiper, Klaus Wirth
-
Publication number: 20140045906Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: August 7, 2013Publication date: February 13, 2014Inventors: Melissa Fleury, Adam D. Hughes
-
Publication number: 20130330366Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Adam D. Hughes, Melissa Fleury
-
Publication number: 20130261158Abstract: The present invention relates to fungicide N-(2-phenoxyethyl)carboxamide derivatives of formula (I), their aza, thia and sila analogues, their process of preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. Formula (1) wherein A, T, W, X, n and Z3 to Z7 represent various substituents.Type: ApplicationFiled: July 30, 2009Publication date: October 3, 2013Inventors: Samir Bennabi, Jurgen Benting, Stephane Brunet, Philippe Desbordes, Peter Dahmen, Stephanie Gary, Marie-Claire Grosjean-Cournoyer, Rachel Rama, Philippe Rinolfi, Valerie Toquin, Arnd Voerste, Ulrike Wachendorff-Neumann
-
Publication number: 20130237578Abstract: The present invention provides compounds of Formula I: along with pharmaceutical compositions containing the same, and methods of use thereof in subjects in need of treatment.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: Eisai R&D Management Co., Ltd.Inventors: Mark Spyvee, Takashi Sataoh, Jonathan Eric Carlson
-
Publication number: 20130210883Abstract: The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Inventors: Johannes Grillari, Rolf Breinbauer, Martina Schweiger, Matthias Romauch, Robert Zimmermann, Nicole Mayer, Elisabeth Schraml, Klaus Fortschegger, Regina Grillari
-
Patent number: 8383622Abstract: Disclosed is a compound which is useful as an 11?-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is a group represented by the formula: Ring B is optionally substituted heteroaryl, provided that optionally substituted isoxazole is excluded, or optionally substituted heterocycle, R1 is hydrogen or optionally substituted alkyl, R2 is —OR5, —SR5, halogen, halogenated alkyl or the like, R3 is optionally substituted alkyl or the like, R4 is optionally substituted alkyl or the like, R5 is optionally substituted alkyl or the like, R6 is hydrogen or the like, R7 and R8 are each independently hydrogen or the like, R10 and R11 are each independently hydrogen or the like, R12 is optionally substituted alkyl or the like, m and p are each independently integer of 1 to 3.Type: GrantFiled: May 7, 2008Date of Patent: February 26, 2013Assignee: Shionogi & Co., Ltd.Inventors: Koji Masuda, Tomoyuki Ogawa, Takuji Nakatani
-
Publication number: 20130046004Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: ApplicationFiled: January 26, 2011Publication date: February 21, 2013Applicant: SANOFIInventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Thomas Olpp, Bodo Scheiper, Klaus Wirth
-
Publication number: 20120259128Abstract: Disclosed is an adamantanamine derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. Disclosed is a compound represented by the formula (II): wherein R10 is a group represented by the formula: —(CR13R14)m-NR12—R11 or the like.Type: ApplicationFiled: December 20, 2010Publication date: October 11, 2012Applicant: SHIONOGI & CO., LTD.Inventors: Tomoyuki Ogawa, Koji Masuda
-
Publication number: 20120259113Abstract: In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: January 9, 2012Publication date: October 11, 2012Applicant: THERAVANCE, INC.Inventors: Brooke Blair, Paul R. Fatheree, Melissa Fleury, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Michael Wilson
-
Publication number: 20120213806Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
-
Publication number: 20120213807Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Cameron Smith
-
Publication number: 20120130080Abstract: Disclosed is a method for preparing a compound of Formula 1 comprising contacting a compound of Formula 2 with a metal cyanide reagent, a copper(I) salt reagent, an iodide salt reagent and at least one compound of Formula 3 wherein R1 is NHR3 or OR4; R2 is CH3 or Cl; R3 is H, C1-C4 alkyl, cyclopropyl, cyclopropylcyclopropyl, cyclopropylmethyl or methylcyclopropyl; R4 is H or C1-C4 alkyl; X is Br or Cl; and R5, R6, R7, R8 and R9 are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula 4 wherein R12, R13, R14 and Z are as defined in the disclosure, using a compound of Formula 1 characterized by preparing the compound of Formula 1 by the method disclosed above or using a compound of Formula 1 prepared by the method disclosed above.Type: ApplicationFiled: December 17, 2008Publication date: May 24, 2012Inventors: Donald J. Dumas, Albert Loren Casalnuovo
-
Publication number: 20110269971Abstract: Disclosed is a process for producing 1-hydroxy-4-aminoadamantane.Type: ApplicationFiled: July 15, 2011Publication date: November 3, 2011Applicant: SHIONOGI & CO., LTD.Inventor: Hideaki Watanabe
-
Publication number: 20110224273Abstract: A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are also described.Type: ApplicationFiled: September 9, 2010Publication date: September 15, 2011Applicant: AstraZeneca ABInventors: Martin John Packer, James Stewart Scott, Andrew Stocker, Paul Robert Owen Whittamore
-
Patent number: 7951953Abstract: This invention relates to a method for preparing a compound of Formula 1 wherein L, R1, R2 and X are as defined in the disclosure, comprising contacting a 2 pyrazoline of Formula 2 with bromine at a temperature of at least about 80° C. (Formula 1) (Formula 2). This invention also discloses preparation of a compound of Formula 3 wherein X, Z, R5, R6, R7, R8a, R8b and n are as defined in the disclosure, using a compound of Formula 1a wherein R10 is as defined in the disclosure, prepared by the aforesaid method for preparing a compound of Formula 1. (Formula 3) (Formula 4).Type: GrantFiled: March 14, 2006Date of Patent: May 31, 2011Assignee: E. I. du Pont de Nemours and CompanyInventor: Paul Joseph Fagan
-
Publication number: 20110086405Abstract: Disclosed is a method for producing a hydroxylated form of a compound having an adamantane skeleton, which is useful as an intermediate for functional resins and pharmaceutical products, with high yield and at low cost. Specifically, a hydroxylated form of a compound having an adamantane skeleton can be obtained by using cytochrome P450. More specifically, an N-(5-hydroxy-2-adamantyl)-benzamide derivative can be produced by hydroxylating an N-(2-adamantyl)-benzamide derivative.Type: ApplicationFiled: September 25, 2008Publication date: April 14, 2011Inventors: Taijiro Tomikawa, Yuuichi Mitsuda
-
Patent number: 7910746Abstract: New haloalkyl carboxamides of formula (I) in which R, R1, R2, R3, R4, M and A have the meanings specified in the description, several processes for synthesizing these materials and their use in combating undesirable microorganisms, as well as new intermediate products and their synthesis.Type: GrantFiled: January 22, 2005Date of Patent: March 22, 2011Assignee: Bayer CropScience AGInventors: Ralf Dunkel, Hans-Ludwig Elbe, Benoit Hartmann, Jörg Nico Greul, Kerstin Ilg, Ulrike Wachendorff-Neumann, Peter Dahmen, Karl-Heinz Kuck
-
Patent number: 7834045Abstract: The invention relates to novel N-substituted pyrazolylcarboxanilides of the formula (I) in which R1, R2, R3, and R4 are as defined in the disclosure, to a plurality of processes for preparing these compounds and their use for controlling unwanted microorganisms, and to novel intermediates and their preparation.Type: GrantFiled: October 12, 2004Date of Patent: November 16, 2010Assignee: Bayer CropScience AGInventors: Ralf Dunkel, Hans-Ludwig Elbe, Jörg Nico Greul, Benoit Hartmann, Ulrike Wachendorff-Neumann, Peter Dahmen, Karl-Heinz Kuck
-
Publication number: 20100280251Abstract: Disclosed is a method for preparing a compound of Formula 1 comprising contacting a compound of Formula 2 with a metal cyanide reagent, a copper(I) salt reagent, an iodide salt reagent and at least one compound of Formula 3 wherein R1 is NHR3 or OR4; R2 is CH3 or Cl; R3 is H, C1-C4 alkyl, cyclopropyl, cyclopropylcyclopropyl, cyclopropylmethyl or methylcyclopropyl; R4 is H or C1-C4 alkyl; Y is Br or Cl; X is NR13 or O; n is 0 or 1; and R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula 2 wherein Y is Br and R1 is NHR3 comprising introducing a gas containing bromine into a liquid containing a compound of Formula 4, and further disclosed is a method for preparing a compound of Formula 5 wherein R14, R15, R16 and Z are as defined in the disclosure using a compound of Formula 1 characterized by preparing the compound of Formula 1 by the method disclosed above.Type: ApplicationFiled: December 18, 2007Publication date: November 4, 2010Applicant: E.I. Du Pont De Nemours and CompanyInventors: Joerg Bruening, Gary David Annis, Martin James Currie, Donald J. Dumas, Rafael Shapiro
-
Publication number: 20100240659Abstract: Disclosed is a compound which is useful as an 11?-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: , its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is a group represented by the formula: Ring B is optionally substituted heteroaryl, provided that optionally substituted isoxazole is excluded, or optionally substituted heterocycle, R1 is hydrogen or optionally substituted alkyl, R2 is —OR5, —SR5, halogen, halogenated alkyl or the like, R3 is optionally substituted alkyl or the like, R4 is optionally substituted alkyl or the like, R5 is optionally substituted alkyl or the like, R6 is hydrogen or the like, R7 and R8 are each independently hydrogen or the like, R10 and R11 are each independently hydrogen or the like, R12 is optionally substituted alkyl or the like, m and p are each independently integer of 1 to 3.Type: ApplicationFiled: May 7, 2008Publication date: September 23, 2010Applicant: SHIONOGI & CO., LTD.Inventors: Koji Masuda, Tomoyuki Ogawa, Takuji Nakatani
-
Patent number: 7767827Abstract: Disclosed are pyrazole-1-carboxylate derivatives of the general formula (1), (wherein symbols are as defined in the specification), a process for the production thereof and processes for producing herbicidally active 3-aryloxypyrazole-1-carboxamide derivatives from the above compound and an intermediate therefor. According to this invention, there can be industrially advantageously produced 3-aryloxypyrazole-1-carboxamide derivatives that does not cause chemical damage on crops but exhibits excellent herbicidal activity against weeds that impair the growth of such crops.Type: GrantFiled: May 22, 2006Date of Patent: August 3, 2010Assignees: Kaken Pharmaceutical Co., Ltd., Sagami Chemical Research CenterInventors: Atsushi Uchida, Wakako Yokota, Kenji Hirai, Tomoyuki Yano
-
Publication number: 20100152443Abstract: The present invention provides a pyrazole derivative of the general formula (1), which has an excellent efficacy as an active component for a herbicide, an intermediate for the production thereof, processes for the production thereof, and a herbicide containing the derivative as an active ingredient.Type: ApplicationFiled: February 26, 2010Publication date: June 17, 2010Applicants: SAGAMI CHEMICAL RESEARCH CENTER, KAKEN PHARMACEUTICAL CO., LTD.Inventors: Kenji Hirai, Atsushi Uchida, Atsuko Watanabe, Taeko Abe, Takuya Ueda, Hiroshi Sakurai
-
Publication number: 20100144785Abstract: The present invention relates N-(aromatic, 6-membered, fused, (hetero)aryl-methylene)-N-cycloalkyl carboxamide derivatives, their thiocarboxamide or N-substituted carboximidamide analogues, all of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents O, S, N—Rc, N—ORd, N—NRcRd or N—CN; Z1 to Z3 and B represents an aromatic, 6-membered, fused, (hetero)aryl; their process of preparation; their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.Type: ApplicationFiled: July 31, 2008Publication date: June 10, 2010Applicant: Bayer SASInventors: Philippe Desbordes, Stephanie Gary, Marie-Claire Grosjean-Cournoyer, Benoit Hartmann, Philippe Rinolfi, Arounarith Tuch
-
Publication number: 20100105923Abstract: Disclosed is a process for producing 1-hydroxy-4-aminoadamantane.Type: ApplicationFiled: September 28, 2007Publication date: April 29, 2010Applicant: SHIONOGI & CO., LTD.Inventor: Hideaki Watanabe
-
Publication number: 20100063293Abstract: To provide a process for producing a specific anthranilamide compound or its salt. To provide a process for producing an anthranilamide compound represented by the formula (I) or its salt: wherein each of R1a and R3 which are independent of each other, is halogen or haloalkyl; R2 is cyclopropyl alkyl or cyclobutyl alkyl; and Hal is a chlorine atom or a bromine atom, which comprises a step of selectively halogenating a compound represented by the formula (II): wherein R1a, R2 and R3 are as defined above.Type: ApplicationFiled: December 14, 2007Publication date: March 11, 2010Applicant: ISHIHARA SANGYO KAISHA ,LTD.Inventors: Toru Koyanagi, Kazuhiro Yamamoto, Tetsuo Yoneda, Shigehisa Kanbayashi, Toyoshi Tanimura, Yohei Taguchi, Tatsunori Yoshida
-
Publication number: 20090306372Abstract: Disclosed is a method for preparing a compound of Formula 1 by contacting compound of Formula 2 with R1—NH2 in the presence of a carboxylic acid and a method for preparing a compound of Formula 2 by contacting a compound of Formula 4 with phosphorus tribromide. wherein R1 is H, C1-C4 alkyl, cyclopropyl, cyclopropylmethyl or methylcyclopropyl; R2 is CH3 or Cl; R3 is C1-C6 alkyl or C3-C6 alkenyl, each optionally substituted with up to 3 halogen and up to 1 phenyl; and X is Cl or Br. Also disclosed is a method for preparing a compound of Formula 5 wherein R4, R5, R6 and Z are as defined in the disclosure, using a compound of Formula 1 that is characterized by preparing the compound of Formula 1 by the method above.Type: ApplicationFiled: June 27, 2007Publication date: December 10, 2009Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: Richard F. Davis, Rafael Shapiro, Eric G. Taylor
-
Publication number: 20090182144Abstract: The present invention aims to provide compounds which have an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P1) and which are useful for pharmaceutical purposes. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: [wherein Ar represents a monocyclic heterocyclic ring containing one or two nitrogen atoms, A represents an oxygen atom or the like, Y1, Y2 and Y3 each represent a carbon atom or a nitrogen atom, R1 represents a hydrogen atom, a C1-C6 alkyl group or the like, R2 represents a C1-C6 alkyl group, a C3-C8 cycloalkyl group or the like, R3 represents a C1-C18 alkyl group or the like, R4 represents a hydrogen atom or a C1-C6 alkyl group, and R5 represents a C1-C10 alkyl group or the like].Type: ApplicationFiled: February 6, 2007Publication date: July 16, 2009Applicant: Taisho Pharmaceutical Co., Ltd.Inventors: Naoya Ono, Tetsuo Takayama, Fumiyasu Shiozawa, Hironori Katakai, Tetsuya Yabuuchi, Tomomi Ota, Takeshi Koami, Rie Nishikawa
-
Publication number: 20090170832Abstract: Disclosed is a compound useful as a type I 11?hydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally substituted alkyl or the like, one of R2 and R4 is a group of formula: —Y—R5, wherein Y is —O— or the like, R5 is substituted alkyl (the substituent is optionally substituted cycloalkyl or the like), optionally substituted branched alkyl or the like, the other of R2 and R4 is hydrogen or optionally substituted alkyl, R3 is a group of formula: —C(?O)-Z-R6, wherein Z is —NR7— or —NR7—W—, R6 is optionally substituted cycloalkyl or the like, R7 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, X is ?N— or the like, with the proviso that compounds wherein R2 is 2-(morphorino)ethoxy, R3 is N-(1-adamantyl)carbamoyl and R1 is benzyl are excluded.Type: ApplicationFiled: November 20, 2006Publication date: July 2, 2009Applicant: SHIONOGI & CO., LTD.Inventors: Noriyuki Kurose, Mikayo Hayashi, Tomoyuki Ogawa, Koji Masuda, Eiichi Kojima
-
Patent number: 7541377Abstract: This invention provides compounds of Formula I, and N-oxides and salts thereof wherein A, B, R1 through R5, R7 through R9, X and Y are as defined in the disclosure. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula I. Also disclosed are compositions for controlling an invertebrate pest comprising the compounds of Formula I.Type: GrantFiled: January 31, 2007Date of Patent: June 2, 2009Assignee: E.I. du Pont de Nemours and CompanyInventors: Bruce Lawrence Finkelstein, George Philip Lahm, Stephen Frederick McCann, Thomas Paul Selby, Ying Song, Thomas Martin Stevenson
-
Publication number: 20090137611Abstract: The present invention relates to N-cyclopropyl-sulfonylamide derivatives of formula (I) wherein the substituents are cyclic groups, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions: (I)Type: ApplicationFiled: April 5, 2007Publication date: May 28, 2009Inventors: Hans-Georg Schwarz, Sandra Gassmann, Karl-Heinz Kuck, Peter Dahmen, Ulrike Wachendorff-Neumann, Stephane Carbonne, Stephanie Gary, Christopher Steele, Alain Villier, Jean-Pierre Vors
-
Publication number: 20090018345Abstract: Disclosed are pyrazole-1-carboxylate derivatives of the general formula (1), (wherein symbols are as defined in the specification), a process for the production thereof and processes for producing herbicidally active 3-aryloxypyrazole-1-carboxamide derivatives from the above compound and an intermediate therefor. According to this invention, there can be industrially advantageously produced 3-aryloxypyrazole-1-carboxamide derivatives that does not cause chemical damage on crops but exhibits excellent herbicidal activity against weeds that impair the growth of such crops.Type: ApplicationFiled: May 22, 2006Publication date: January 15, 2009Applicants: KAKEN PHARMACEUTICAL CO., LTD., SAGAMI CHEMICAL RESEARCH CENTERInventors: Atsushi Uchida, Wakako Yokota, Kenji Hirai, Tomoyuki Yano
-
Patent number: 7425640Abstract: The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.Type: GrantFiled: October 26, 2005Date of Patent: September 16, 2008Assignee: Schering CorporationInventors: Alan B. Cooper, Hugh Y. Zhu, James J-S Wang, Jagdish A. Desai, Gerald W. Shipps, Jr., Patrick J. Curran, D. Allen Annis, Huw M. Nash, Viyyoor M. Girijavallabhan
-
Patent number: 7183306Abstract: A compound of the formula (I): wherein R1 is hydrogen or lower alkyl; R2 is lower alkyl, etc.; R3 is lower alkoxy, etc.; R4 is hydroxy, etc.; X is O, S, etc.; Y is CH or N; Z is lower alkylene or lower alkenylene; and m is 0 or 1; or salts thereof, which are useful as a medicament.Type: GrantFiled: November 14, 2003Date of Patent: February 27, 2007Assignee: Astellas Pharma Inc.Inventors: Fumiyuki Shirai, Hidenori Azami, Natsuko Kayakiri, Kazuo Okumura, Katsuya Nakamura
-
Patent number: 7115749Abstract: The present invention provides compounds of formula I wherein X and R1–R7 are as defined herein.Type: GrantFiled: October 26, 2005Date of Patent: October 3, 2006Assignee: Schering CorporationInventors: Gerald W. Shipps, Jr., Tong Wang, Kristin E. Rosner, Patrick J. Curran, Alan B. Cooper, Viyyoor M. Girijavallabhan
-
Patent number: 7109228Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: April 5, 2002Date of Patent: September 19, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
-
Patent number: 6949550Abstract: The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.Type: GrantFiled: November 26, 2002Date of Patent: September 27, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Mimi L. Quan, Ruth R. Wexler